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ALI = acute lung injury; ARF = acute renal failure; ICU = intensive care unit; FiO2 = fractional inspired oxygen; PEEP = positive end-expiratory pres-
sure; SOFA = Sepsis-related Organ Failure Assessment.
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The 15th Annual European Society of Intensive Care
Medicine (ESICM) meeting opened in Barcelona, Spain on
30 September 2002, with ‘Clinical research to improve
outcome’ as a motto. Participants could attend thematic and
educational sessions that covered a wide range of topics.
Roundtable meetings and pro/con debates between experts
in various areas were also held. Space was given to abstract
presentations (oral presentations, poster symposia and
sessions); there were more than 500 abstracts presented,
generating interesting debates among the participants.
Another unique aspect of the congress was that entire
sections were devoted to nurses and physiotherapists,
making them active contributors to the advancement of
intensive care research.
Such a broad range of topics and activities renders extensive
coverage of the congress difficult. We therefore opted to
focus on highlights, acknowledging that all of the presented
works were important to the development of critical care
medicine.
Interesting work was presented in the session entitled
‘Results from the most recent clinical trials in intensive care
medicine’.
The SOAP study: preliminary results
Jean-Louis Vincent from the Free University of Brussels,
Belgium presented preliminary data from the Sepsis
Occurrence in the Acutely ill Patient (SOAP) study, which
was conducted over the period 1–15 May 2002. The goal of
the study was to determine the incidence of severe sepsis
and septic shock in intensive care unit (ICU) patients in
European centres. Over the 2 weeks, 3147 patients from
198 centres were studied. Epidemiological data and other
clinical data related to severity of disease, organ dysfunction,
survival status and treatment aspects were recorded. Patient
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Abstract
The 15th Annual European Society of Intensive Care Medicine Meeting opened in Barcelona, Spain on
September 30, 2002. This report focuses on some highlights of this congress. Preliminary data from
the Sepsis Occurrence in the Acutely ill Patient (SOAP) study are presented, as are findings from the
Assessment of Low Tidal Volume and Elevated End-Expiratory Volume to Obviate Lung Injury
(ALVEOLI) study, which compared higher positive end-expiratory pressure (PEEP)/lower fractional
inspired oxygen (FiO2) with lower PEEP/higher FiO2 strategies. We also present a study that compared
continuous with intermittent renal replacement therapies. Finally, the seven posters that received an
award are summarized.
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characteristics and some results are summarized in Table 1
[1–3]. The incidence of infection varied according to
geographical location, and was highest in Portugal and
lowest in Switzerland. The lung was the most commonly
reported source of infection. Gram-positive and Gram-
negative pathogens were equally present in the infected
patients. Among Gram-negative cases, Pseudomonas spp.
and Escherichia coli were the most frequently encountered
pathogens.
Haemodynamic support in patients with sepsis was most
often accomplished with norepinephrine (noradrenaline). For
fluid resuscitation, hydroxyethyl starches and gelatins were
used in almost equal proportions (34.2% versus 30.6%).
That study is of paramount importance because it provides
important insights into the incidence of septic states.
Moreover, it is clear that the data regarding epidemiological
features, severity of disease, organ dysfunction and treatment
aspects will generate important conclusions.
High versus low positive end-expiratory
pressure: the ALVEOLI study
Dr Arthur Slutsky from Toronto, Canada presented findings
from the Assessment of Low Tidal Volume and Elevated End-
Expiratory Volume to Obviate Lung Injury (ALVEOLI) study,
which compared the use of higher positive end-expiratory
pressure (PEEP)/lower fractional inspired oxygen (FiO2)
versus lower PEEP/higher FiO2 in patients with acute lung
injury (ALI) and acute respiratory distress syndrome. That
prospective, randomized, multicentre study was based on the
presumption that mortality from ALI and acute respiratory
distress syndrome could be reduced using a strategy
designed to prevent lung injury from repeated collapse of
alveoli at end-expiration. The hypothesis was that both
strategies would result in the same mortality rate.
Inclusion criteria were the classical criteria used to define ALI
[4]. Among the exclusion criteria, the most important were
physician refusal to use assisted/controlled ventilation mode
for 12 hours, a delay to treatment of more than 36 hours from
satisfaction of the inclusion criteria, and various medical
conditions that precluded inclusion.
The primary outcome was mortality before hospital discharge
or on day 60 after randomization, with the latter group being
classified as survivors if they were still alive on day 60. Some
secondary outcomes were ventilator free days and ICU free
days.
Patients were ventilated with a tidal volume of 6cm3/kg
predicted body weight, aiming for a plateau pressure of less
than 30cmH2O. Target ranges for oxygenation were an
arterial oxygen tension between 55 and 80mmHg, or an
oxygen saturation between 88% and 95%. The first 150
patients received a recruitment manoeuvre, but this practice
was stopped thereafter. For both groups, oxygenation was
maintained in the target range using a table of PEEP/FiO2
combinations.
The investigators planned to recruit 750 patients, so that
there would be an 89% chance of finding a 10% significant
decrease in mortality. Intermediate analysis was planned after
250 and 500 patients had been recruited. The study was
prematurely stopped after a recommendation from an
independent data and safety monitoring board. ‘Futility’ was
stated as the reason for ending the study after enrollment of
550 patients.
Baseline characteristics of the patients at enrollment were
dissimilar between the two groups. Patients in the higher
PEEP group were older and had a lower ratio of arterial
oxygen tension (PaO2) to fractional inspired oxygen (FiO2)
Table 1
Sepsis Occurrence in the Acutely ill Patient (SOAP) study:
patient characteristics
Characteristic Value
Age (years); median (interquartile range) 64 (50–74)
Provenance from medical wards 1951 (62)
Mean SAPS II score [1] 34
SOFA score values [2] at inclusion 5
SOFA maximum 6
SOFA mean during study period 4
ICU duration of stay (days) 3
Hospital duration of stay (days) 15
ICU mortality 582 (18.5)
Infection* 1177 (37.4)
Clinical suspicion of infection 966 (30.7)
Positive microbiological cultures 906 (28.8)
Antibiotic therapy 2001 (63.6)
Sepsis [3] 1091 (34.7)
Severe sepsis [3] 928 (29.5)
Septic shock [3] 462 (14.7)
Presence of venous central lines 2272 (72.2)
Presence of pulmonary artery catheter 481 (15.3)
Mechanical ventilation 2023 (64.3)
Haemodialysis 142 (4.5)
Continuous veno-venous haemofiltration 211 (6.7)
Shown is a summary of patient characteristics from the SOAP study
(n=3147). Values are expressed as number (%), unless otherwise
stated. *Defined as clinical suspicion of infection and/or positive
microbiological culture plus use of antibiotic therapy. ICU, intensive
care unit; SAPS, Simplified Acute Physiology Score; SOFA,
Sequential Organ Failure Assessment.93
than did those in the control group. However, Acute
Physiology and Chronic Health Evaluation III scores were
similar between the groups. No difference was observed
between the groups with respect to mortality (27.6% in the
lower PEEP group versus 24.9% in the higher PEEP group;
P=0.44), even after adjustment for differences in age and
ratio of pressure to flow. Dr Slutsky concluded that, on the
basis of these findings, the higher PEEP/lower FiO2 strategy
should not routinely be favoured over the lower PEEP/higher
FiO2 strategy, even though there was a trend toward excess
mortality in the lower PEEP group.
Acute renal failure: continuous versus
intermittent renal replacement therapy
Dr Hans Ulrich Rothen from Bern, Switzerland presented
findings from his study on outcomes of patients with acute
renal failure (ARF) who require dialysis. Because mortality in
this population may reach 50–90%, newer therapies to
decrease mortality are urgently needed. Continuous renal
replacement therapy has potential advantages over
conventional therapy, including improved haemodynamic
stability, gradual removal of toxins and inflammatory
mediators, and optimal fluid management, along with the
ability to administer parenteral nutrition without causing fluid
overload. The study was conducted to identify whether these
potential benefits might translate into improvement in renal
and patient outcomes. The aim of the study was therefore to
compare both strategies randomly with mortality in the ICU
as the primary outcome. Totals of 70 and 55 comparable
patients were enrolled in the continuous and intermittent
groups, respectively. No differences were observed with
regard to haemodynamic stability in the groups, although
colloids were administered more frequently in the intermittent
group. The overall mortality and recovery from ARF were the
same in both groups. The authors of that study concluded
that their data do not support the use of one therapy over the
other as a way to improve survival in patients with ARF in the
ICU. However, they emphasized the small size of their study,
which might account for the inconclusive results.
Levosimendan: a new therapy for
decompensated heart failure?
A new molecule was the topic of many presentations. Ferenc
Follath from Zurich, Switzerland and Mervyn Singer from
London, UK chaired a session entitled ‘An evolving role for
levosimendan in acute decompensated hearth failure’. The
background of the discussion was that, actually, there is little
evidence for improved outcome in patients treated with current
β-agonists or phosphodiesterase inhibitors. There is therefore
growing interest in finding alternative therapeutic agents to
treat patients with acute heart failure. Levosimendan is a
calcium sensitizer with a dual mechanism of action. It sensitizes
troponin C to calcium, leading to an improvement in
contractility during systole. As such, decreased calcium
availability during diastole leads to better diastolic relaxation by
avoiding diastolic calcium overload. Both of these phenomena
result in improved contractility at a lower energy cost.
Moreover, to a degree, levosimendan also has vasodilator
properties by activating adenosine triphosphate–potassium
sensitive channels. With its unique inotropic and vasodilatory
properties, levosimendan can increase cardiac output without
increasing myocardial oxygen demand. A recent study [5]
showed its efficacy and safety as compared with dobutamine
in patients with severe cardiac failure.
Poster awards
The European Society of Intensive Care Medicine chose seven
poster award winners (titles given in the headings below).
Documentation of respiratory rate for acutely sick
hospital in-patients: an observational study
This study [6] showed that it is important that respiratory rate
be monitored, and that it should be recorded regularly in
ward patients because an increased rate is a possible sign of
impending clinical deterioration.
NOSOREF: a French survey of nosocomial infections
surveillance in intensive care units
This survey [7] showed significant differences in surveillance
and diagnosis of nosocomial infections in 244 surveyed
ICUs. Of the ICUs, 72% specifically reported nosocomial
infections and 77% performed searches for multiresistant
bacteria at ICU admission.
Inhibition of neutrophil chemotaxis by protein C and
activated protein C
The conclusion of this study [8] was that protein C and
activated protein C can inhibit neutrophil chemotaxis. The
results also suggest that neutrophils express endothelial
protein C receptor, signalling antimigratory stimuli.
Episepsis study: French severe sepsis epidemiology in
2001
This epidemiological study [9] included 3833 patients,
17.3% of whom developed severe sepsis. Actual hospital
mortality for these patients was 44%. Of the patients, 11%
were still hospitalized at 2 months.
Spanish study of organ dysfunction and its evaluation
with the daily SOFA score
Daily assessment of Sepsis-related Organ Failure
Assessment (SOFA) score during the 5 days following
admission was useful in predicting hospital mortality in ICU
patients in this study [10]. The authors also developed a
model including SOFA max (maximum value), SOFA min
(minimum value), SOFA tend (tendency) and age that was
able to produce a receiver operating curve with r=0.811.
Hepatic venous gas and free radical as indicator of
oxygen metabolism during hepatic arterial clamp
This animal study [11] showed that portal hepatic venous
oxygen, oxygen content and hepatic venous oxygen
Available online http://ccforum.com/content/7/1/9194
saturation, but not pH, decreased after hepatic artery
clamping. Hepatic venous oxygen saturation was also related
to hepatic parenchymal oxygen metabolism.
Efficacy of recombinant erythropoietin in the critically
ill
This prospective, multicentre, randomized, double-blind,
controlled trial of 1302 patients compared the use of human
recombinant erythropoietin with placebo [12]. Patients who
received the therapy were less likely to be transfused (relative
risk 0.84, 95% confidence interval 0.76–0.92) than were the
placebo group. The treated group also received fewer red
blood cell units when they were transfused, and the increase
in haemoglobin was greater. However, mortality was not
different between the groups.
Next year
Next year, the 16th Annual Congress will be held in
Amsterdam, and the motto will be ‘Scientific foundation for
clinical excellence’. We hope that the meeting will encourage
intense exchange between participants, as it did this year.
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